➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Merck
Moodys
Johnson and Johnson
Medtronic

Last Updated: June 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LEE011


Email this page to a colleague

« Back to Dashboard

What is the drug development status for LEE011?

LEE011 is an investigational drug.

There have been 74 clinical trials for LEE011. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are one hundred and seventy-nine US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for LEE011
TitleSponsorPhase
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesNational Cancer Institute (NCI)Phase 1
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesEmory UniversityPhase 1
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNovartis PharmaceuticalsPhase 2

See all LEE011 clinical trials

Clinical Trial Summary for LEE011

Top disease conditions for LEE011
Top clinical trial sponsors for LEE011

See all LEE011 clinical trials

US Patents for LEE011

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LEE011   Try Before You Buy Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Try Before You Buy
LEE011   Try Before You Buy Ribociclib intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN)   Try Before You Buy
LEE011   Try Before You Buy Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH)   Try Before You Buy
LEE011   Try Before You Buy Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LEE011

Drugname Country Document Number Estimated Expiration Related US Patent
LEE011 Australia AU2014348657 2033-11-13   Try Before You Buy
LEE011 Australia AU2017245411 2033-11-13   Try Before You Buy
LEE011 Australia AU2019246853 2033-11-13   Try Before You Buy
LEE011 Brazil BR112016010716 2033-11-13   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.